UBM’s pharma portfolio announces a new, independently branded biopharma event, BioLive, next year in Madrid (October 9-11, 2018, at IFEMA, Feria de Madrid) - specifically for bioprocessing and manufacturing.
UBM says the new event has been created after independent research identified a gap in the market for a global exhibition and content platform that could establish global leadership across the entire bio manufacturing value chain.
BioLive will serve as a global hub for upstream and downstream processing and manufacturing, connecting biotechs, big pharma and service providers including CDMOs and CROs from early stage development to commercial manufacturing and regulatory services. It will also feature biogeneric and bioinnovator audiences through to manufacturing and laboratory specialists.
Analyst research indicated that running the new event in parallel to its contract services (ICSE) and small molecule (CPhI Worldwide) exhibitions would create natural synergies and establish the first global hub covering the entire biopharma and pharma supply chain.
“It’s a hugely exciting time for the bio industry globally, and we expect rapid growth in what is now a maturing supply chain,” says Rutger Oudejans, brand director at UBM. "Independent research showed a dissatisfaction amongst existing options, and we have identified that we can provide broader depth in bio manufacturing and processing, whilst capitalizing on our collective portfolio strength to bring additional value by combining the small and large molecule worlds together with contract services. It is the first to provide an ecosystem to bring together the bio development and manufacturing sectors. But it also enables companies and professionals involved across the full pharma value chain of both small and large molecules to learn from each other and evolve new strategies to overcome the challenges in bio processing and manufacturing.”
Attendees at BioLive will benefit from a mixture of science and technology content - including presentations and conferences on the latest bio innovations and techniques - alongside specialized business development and partnering programs to help them directly match with the most appropriate partners.
BioLive will help big pharma’s bio divisions and biopharma giants to assess the specific niche services they need, such as analytics and testing. Conversely, the event will empower the small- and medium-sized bio innovators who want to feed new therapies into the development pipelines of larger companies. Bio innovators will also be able to look for the external partners they need to push forward their drug development and commercialization programs.
Additionally, BioLive will include the producers of specialized bio lab equipment - such as high-performance liquid chromatography - needed for biopharmaceutical research, QC and regulatory submissions.
“There is great potential in bringing the bio community together under the auspices of one new global event - running at the same time as CPhI Worldwide. The launch of BioLive will help accelerate the development of the bio supply chain, improve knowledge exchange and create a more collaborative bio/pharma environment,” says Eric Langer, president and managing partner, BioPlan Associates.